REC-1245 / Recursion Pharma - LARVOL DELTA

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "Upcoming milestones: REC-617 (CDK7): On track to initiate CDK7 combination studies in 1H25, additional monotherapy data expected in 2H25; REC-7735 (PI3Kα H1047R): Preclinical studies ongoing with development candidate expected in 2H25; REC-1245 (RBM39): Early Phase 1 safety and PK monotherapy data expected in 1H26."

P1 data • P1/2 data • Pipeline update • Solid Tumor

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma (GlobeNewswire) - "Recursion...today announced that the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma....The DAHLIA clinical trial is an open-label Ph1/2 study to characterize the safety, tolerability, PK, PD, and preliminary activity (ORR) of REC-1245 and to identify the maximum tolerated dose (MTD) and / or recommended phase 2 dose (RP2D)."

Trial status • Lymphoma • Oncology • Solid Tumor

No information: A Study of REC-1245 in Participants with Unresectable, Locally Advanced, or Metastatic Cancer (clinicaltrials.gov) - P1/2 | N=85 | Recruiting | Sponsor: Recursion Pharmaceuticals Inc.

Metastases • New P1/2 trial • Hematological Malignancies • Lymphoma • Oncology

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma (GlobeNewswire) - "Recursion...announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma....The Phase 1/2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential monotherapy efficacy of REC-1245, and is expected to initiate in Q4 2024."

IND • New P1/2 trial • Lymphoma • Solid Tumor